Publications by authors named "D Planchard"

Claim this Profile
T
Trastuzumab Deruxtecan in Patients with HER2-Overexpressing Non-Small Cell Lung Cancer: Results From Part 1 of the Open-label, Multicenter, Phase 1b DESTINY-Lung03 Trial.
David Planchard, Hye Ryun Kim, Thatthan Suksombooncharoen, Rubi Li, Diego Cortinovis

J Thorac Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The first United Arab Emirates expert consensus recommendations for the diagnosis and management of early and advanced non-small cell lung cancer.
Humaid Al Shamsi, Nadia Abdelwahed, Hassan Jaafar, Hassan Ghazal, Hampig Raphael Kourie, David Planchard

Future Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world outcomes of second-line carboplatin plus pemetrexed after first-line osimertinib in EGFR-mutant advanced NSCLC: An international multicentre cohort study.
Igor Gomez-Randulfe, Federico Monaca, Ornella Cantale, Maria Lucia Reale, Loredana Mrak, David Planchard

Lung Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trastuzumab Deruxtecan for ERBB2-Mutant Metastatic Non-Small Cell Lung Cancer With or Without Brain Metastases: A Secondary Analysis of Randomized Clinical Trials.
Pasi A Jänne, David Planchard, Koichi Goto, Egbert F Smit, Adrianus Johannes de Langen

JAMA Netw Open· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The rechallenge benefit score: A clinical decision tool for patients progressing after immunotherapy.
Caroline Plazy, Mohamed Boussena, Linh Nguyen Phuong, Jean Baptiste Assié, Emmanuel Grolleau, David Planchard

Eur J Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis